{"id":"W4409493832","doi":"10.1182/bloodadvances.2024015719","title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovation Cluster (Canada)","funders":"MorphoSys; Swedish Orphan Biovitrum; Incyte; Regeneron Pharmaceuticals; Gilead Sciences; Sanofi; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Bispecific antibody; Refractory (planetary science); Lymphoma; Antibody therapy; Medicine; Antibody; CAR T-cell therapy; Cancer research; Oncology; Internal medicine; Immunology; T cell; Chimeric antigen receptor; Biology; Monoclonal antibody; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003141882,0.0002843698,0.0006804487,0.0004833478,0.00004546945,0.00001810038,0.0002543732,0.0001673139,0.0008631068],"category_scores_gemma":[0.00004025316,0.0002272057,0.0002218448,0.0006755214,0.0001345769,0.0001355187,0.00007463719,0.0002787767,0.00003105277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006794182,"about_ca_system_score_gemma":0.0002199646,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004480345,"about_ca_topic_score_gemma":0.000138214,"domain_scores_codex":[0.9979242,0.0001126979,0.0004908565,0.0004784252,0.0004771149,0.0005167142],"domain_scores_gemma":[0.9987452,0.0002372683,0.0001166538,0.0006725343,0.0001278802,0.0001004642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001049516,0.00502466,0.6571935,0.0003301066,0.0001158679,0.0001711887,0.0004043721,0.000002391574,0.3245775,0.00005956144,0.0002198497,0.01085145],"study_design_scores_gemma":[0.03514592,0.0007506997,0.2594473,0.0002646688,0.00007835125,0.000007919019,0.001040007,0.00001075895,0.2732441,0.0001685609,0.4294986,0.0003431338],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9529883,0.03310324,0.00001608156,0.0003869362,0.000223759,0.0006555758,0.00003302784,0.00005138303,0.01254176],"genre_scores_gemma":[0.9711694,0.00697718,0.0004044073,0.0003421725,0.00007195838,0.00006595413,0.00002357495,0.00004280771,0.02090251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4292788,"threshold_uncertainty_score":0.9450414,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009952427921185381,"score_gpt":0.3055829094655686,"score_spread":0.2956304815443832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}